Emergency postexposure vaccination with vesicular stomatitis virus-vectored ebola vaccine after needlestick

JAMA - Journal of the American Medical Association

Volumn 313, Issue 12, 2014, Pages 1249-1255

  Lai, Lilin ^a   Davey, Richard ^b   Beck, Allison ^a   Xu, Yongxian ^a   Suffredini, Anthony F ^b   Palmore, Tara ^b   Kabbani, Sarah ^a   Rogers, Susan ^a   Kobinger, Gary ^c   Alimonti, Judie ^c   Link, Charles J ^d   Rubinson, Lewis ^e   Ströher, Ute ^f   Wolcott, Mark ^g   Dorman, William ^g   Uyeki, Timothy M ^f   Feldmann, Heinz ^h   Lane, H Clifford ^b   Mulligan, Mark J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d NEWLINK GENETICS   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1BETA; INTERLEUKIN 2; MATRIX PROTEIN; TUMOR NECROSIS FACTOR; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY DETECTION; ARTHRALGIA; ARTICLE; CASE REPORT; CHILL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FATIGUE; FEVER; HEADACHE; HUMAN; INFORMED CONSENT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INNATE IMMUNITY; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MYALGIA; NAUSEA; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; PATIENT TRANSPORT; PHYSICIAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; SIERRA LEONE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED STATES; VACCINATION; VESICULOVIRUS; VIRUS GENE; VIRUS REPLICATION; COMPLICATION; GENE VECTOR; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; TRANSMISSION;

ADULT; EBOLA VACCINES; EBOLAVIRUS; FEVER; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; NEEDLESTICK INJURIES; PHYSICIANS; POST-EXPOSURE PROPHYLAXIS; SIERRA LEONE; VACCINATION; VESICULOVIRUS;

EID: 84925436702     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1995     Document Type: Article

References (21)

1. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56(2):271-293.
2. Marzi A, Feldmann H, Geisbert TW, Falzarano D. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef. 2011;S1(4).
3. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007;3(1):e2.
4. Rubinson L. From clinician to suspect case:my experience after a needle stick in an Ebola treatment unit in Sierra Leone. Am J Trop Med Hyg. 2015;92(2):225-226.
5. Trombley AR, Wachter L, Garrison J, et al. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and new world hantaviruses. Am J Trop Med Hyg. 2010;82(5):954-960.
6. US Food and Drug Administration. Authorization of emergency use of an in vitro diagnostic device for detection of Ebola Zaire virus: availability. Fed Regist. 2014;79:55804.
7. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208(1):181-193.
8. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453(7195):667-671.
9. Edupuganti S, Eidex RB, Keyserling H, et al; YF-Ig Study Team. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. Am J Trop Med Hyg. 2013;88(1):172-177.
10. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710-722.
11. Athearn K, Sample CJ, Barefoot BE, Williams KL, Ramsburg EA. Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1β. PLoS One. 2012;7(10):e46516.
12. Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol. 2008;15(3):460-467.
13. Günther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis. 2011;204(suppl 3):S785-S790.
14. National Institute of Allergy and Infectious Diseases. NIH News: Ebola vaccine trial opens in Liberia [press release]. February 2, 2015.
15. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4(11):e1000225.
16. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729):1896-1905.
17. Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012;109(44):18030-18035.
18. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47-53.
19. Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012;93(pt 12):2529-2545.
20. Williams KJ, Qiu X, Fernando L, Jones SM, Alimonti JB. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection. Viral Immunol. 2015;28(1):51-61.
21. Breman JG, Johnson KM. Ebola then and now. N Engl J Med. 2014;371(18):1663-1666.